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In 1906 Dale1 showed that an extract from the posterior pituitary
gland stimulated uterine activity. Three years later Blair Bell2
reported its efficacy in the treatment of postpartum haemorrhage.
In 1927 Bourne and Burn concluded that oxytocin may be valuable
in cases where labour is prolonged secondary to ‘sluggish pains’.3
Du Vigneaud was the first person to synthesise this polypeptide
hormone and in 1955 received the Nobel Prize for his work.4 
Oxytocin is a nonapeptide hormone, produced in the
hypothalamus, stored in the posterior pituitary gland, and secreted
in a pulsatile way.  Oxytocin receptors are found in the
myoepithelial cells of the breast, the myometrium and the
decidua.5 Myometrial oxytocin sensitivity increases through
pregnancy.6 The concentration of myometrial receptors increases
towards term and may be particularly high in patients with
preterm labour.7 Myometrial gap junctions also increase as
gestation advances, possibly enhancing the sensitivity of the
myometrium to uterotonic agents and helping to maintain
effective contractions.8
In pregnancy, oxytocinase (circulating aminopeptidase) is
produced by the placenta and significantly increases the metabolic
clearance rate of oxytocin.9 The exact pharmacological half-life of
oxytocin is controversial10 but available data suggest that a stable
uterine response is obtained 40 - 60 minutes after initiating a
constant-dose infusion.11,12 Therefore the physiological half-life may
be close to 10 minutes, since approximately four ‘half-lives’ are
required to obtain constant plasma levels.5
Oxytocin is one of the most commonly used drugs in labour,
and there are many different dosage regimens.  However, if
oxytocin is used incorrectly it can lead to major complications such
as fetal hypoxia, hyperstimulation of the uterus and even uterine
rupture.  The aim of this study was to examine the use of oxytocin
by practising obstetricians in South Africa.  
Methods
A specially designed questionnaire was drawn up and reviewed
by a panel of practising obstetricians.  A total of 350 questionnaires
(in both English and Afrikaans) were distributed to specialists
according to an address list obtained from the South African
Society of Obstetricians and Gynaecologists. Each questionnaire
was divided into two sections: the first dealt with induction of
labour and the second with augmentation of labour.  Every
questionnaire was accompanied by a covering letter explaining the
aim of the study, as well as a stamped self-addressed envelope.
All the questionnaires were returned anonymously. The forms
were distributed between August and December 2002.
Results
Of the 350 questionnaires distributed, 185 questionnaires were
returned.  Eleven doctors were either abroad or retired, and
therefore not practising in South Africa. One hundred and
seventy-four questionnaires were processed, giving a response
rate of 51.3% (Table I). 
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Table I.  Oxytocin use in pregnancy — results of questionnaire
Question Answer (N) Percentage
Induction of labour
1.  Oxytocin use with unfavourable cervix Yes   16 9.2 
No   157 90.8 
2.  Oxytocin use with intact membranes Yes   68 39.5 
No   104 60.5 
3. Time after ROM
Primigravida
Immediately 32 18.9 
1  hour 62 36.7 
6  hours 36 21.3 
12 hours 11 6.5 
24 hours 10 5.9 
Other 17 10.1 
Not at all 1 0.6 
Multigravida 
Immediately 20 11.8 
1  hour 52 30.8 
6  hours 36 33.1 
12 hours 10 5.9 
24 hours 9 5.3 
Other 22 13 
4.  Use with one previous caesarean section Yes   51 29.7 
No   121 70.3 
5.  Use with viable twin pregnancy Yes   62 36.3 
No   109 63.7 
6 .  Use with multigravida Yes  159 94.6 
No   9 5.4 
7 .  Use with grand multipara Yes   47 28.1 
No   120 71.9 
8.   Same regimen as with primigravidas 46 30.3 
Lower dose than with primigravidas 106 69.7 
9.   Fetal heart monitoring 
Fetal stethoscope + intermittent CTG 4 2.4 
Intermittent CTG 38 22.8 
Intermittent + continuous CTG 7 4.2 
Intermittent CTG + doptone 4 2.4 
Continuous CTG 114 68.3 
10. Administering method
Electronic pump 150 90.4 
Non-electronic device 14 8.4 
None of the above 2 1.2 
Augmentation of labour
1.   Oxytocin with intact membranes Yes   71 41.3 
No   101 58.7 
2.   Use with one previous caesarean section Yes   60 34.6 
No   113 65.3 
3.   Use with viable twin pregnancies Yes   68 39.3 
No   105 60.7 
4.   Use with multigravida Yes  159 91.9 
No   14 8.1 
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Induction of labour
In the section dealing with induction of labour, 90.8% of
obstetricians would not use oxytocin in patients who had an
unfavourable cervix (Bishop score of less than 6) and 60.5%
said that they would not consider the use of oxytocin if the
patient had intact membranes.  
If a primigravida’s membranes had ruptured, 18.9% of
clinicians said that they would administer oxytocin
immediately, 36.7% said they would wait 1 hour, and 21.3%
said they would wait 6 hours before starting with an oxytocin
infusion.
In the case of multigravid women, 11.8% of obstetricians said
they would start oxytocin immediately, 30.8% said they would
wait 1 hour, and the majority of clinicians (33.1%) said they
would wait 6 hours.
With regard to previous caesarean sections, 70.3% of
obstetricians said they would not use oxytocin in patients with
a previous lower-segment caesarean section. 
A total of 63.7% of doctors said they would not consider
oxytocin use in a patient with a multifetal pregnancy.  
Most respondents said they would use oxytocin for
induction of labour in multigravid patients; only 5.4% said they
would not use it.  However 71.9% of doctors said they would
not use oxytocin to induce labour in grand-multiparous
patients. Most doctors (69.7%) said they would use a lower-
dose regimen with multigravid than with primigravid patients.  
With regard to monitoring the patient, 68.3% said they
would use continuous cardiotographic (CTG) monitoring while
administering oxytocin, 22.8% said they would use intermittent
CTG monitoring, while the remainder said they would use a
combination of fetal stethoscope and CTG monitoring.  
Augmentation of labour
The second section of the questionnaire dealt with
augmentation of labour.  It showed that 58.7% of obstetricians
would not use oxytocin in a patient with intact membranes and
65.3% would not augment patients who had had a previous
(lower-segment) caesarean section.  
The majority of doctors (60.7%) said they would not use
oxytocin augmentation in a patient with a multifetal
pregnancy.  
The majority of respondents (91.9%) said they would use
oxytocin to augment labour in multigravid women; however if
the patient was a grand multipara, 72.3% said they would not
use oxytocin. In  multiparous patients, 66.4% of doctors said
they would use a lower dose than in primigravidas.  
Most clinicians (74.7%) agreed that the desired number of
contractions is 3 in 10 minutes, whereas 21.1% of doctors
preferred 4 strong contractions in 10 minutes.  Only 3% of
doctors accepted 5 strong contractions in 10 minutes.   Most
obstetricians (71.9%) said they would wait 30 minutes before
increasing the oxytocin dosage if contractions were suboptimal,
while 14.9% said they would increase the dosage every 15
minutes.  
If a prostaglandin analogue was used for induction of labour,
Table I, continued  
5.   Use with grand multipara Yes   48 27.7 
No   125 72.3 
6.   Same regimen as with primigravida 51 33.6 
Lower regimen than with primigravida 101 66.4 
7.   Contractions/10 min 2 :    2 1.2 
3 :   124 74.7 
4 :   35 21.1 
5 :    5 3
8.   Time after prostaglandin (hrs)
1  4 2.6 
2  9 5.8 
3  8 5.1 
4  40 25.6 
5  5 3.2 
6  78 50 
More 12 7.7  
9.  Dosage increase after
15 min 24 14.6 
30 min 119 71.9 
45 min 13 7.9 
60 min 8 4.9 
ROM = rupture of membranes; CTG =  cardiotocogram.
25.6% of obstetricians said they would wait 4 hours before
starting oxytocin infusion,  50% said they would wait at least 6
hours, and 7.7% of respondents said they would wait longer
than 6 hours.
Of the 174 respondents, 73.1% were in private practice, 13.2%
in academic institutions, 11.4% worked in both private practice
and academic institutions, and 2.4% worked in non-academic
government hospitals.  
Discussion
A total of 350 questionnaires were posted and 185 returned, of
which 174 (51.3%) could be processed. According to Babbie 
et al.13 a response rate of 50% or more is adequate for robust
analysis and interpretation. 
Labour is induced when delivery will benefit the health of
the fetus and/or the mother.14 Obstetricians should be familiar
with the indications for induction of labour, and the chance of
successful induction depends a great deal on the condition of
the cervix. According to Hofmeyr,15 the cervix undergoes
physiological change during pregnancy.  In the first trimester
the cervix consists mostly of tightly aligned collagen (50%),
20% smooth muscle and the remainder is ground substance,
including elastin and glycosaminoglycans.  As pregnancy
advances, hyaluronidase increases from 6% to 33%, whereas
other glycosaminoglycans (dermatin and chondroitin), which
bind collagen more tightly, decrease.  Collagenase, the
vascularity of the cervix and its water content increase during
pregnancy. In 1964 Bishop16 designed a pelvic scoring system
(which has since been modified) to assess the condition of the
cervix.  The chance of successful induction with oxytocin
depends a great deal on the Bishop score; a score of ≥ 9 was
associated with a > 50% delivery rate within 5 days without
any intervention. 
Local application of prostaglandin E2 gel (dinoprostone) is
widely used for cervical ripening and induction of labour.17
Ocytocin may also be used for this purpose, but controlled
studies have indicated that oxytocin is not very effective when
the cervix is unfavourable when compared with local
prostaglandins.18 The present study showed that most
obstetricians (90.8%) would not use oxytocin infusion for
induction if the cervix was unfavourable. When induction is
commenced with prostaglandins, the latest evidence-based
guidelines19 specify that the interval between prostaglandin
doses should be 6 hours. However, the shortest safe time
interval between prostaglandin administration and the
initiation of oxytocin use has not yet been established.
According to the manufacturer’s guidelines, oxytocin should
be delayed for 6 - 12 hours following prostaglandin
administration.17 Over 50% of obstetricians in South Africa
follow the abovementioned guidelines.  
Another common method of induction of labour is artificial
rupture of the membranes.  With the HIV pandemic it is vital
to know the patient's HIV status, since amniotomy can lead to
vertical transmission.  There is still uncertainty in the literature
regarding the safe time interval between amniotomy and
commencement of oxytocin infusion.  The general consensus is
that prostaglandins are released during low amniotomy and
this stimulates labour.  Oxytocin should be started 1 hour after
amniotomy to allow the locally released prostaglandins to
facilitate contractions and to avoid possible uterine
hyperstimulation.  The majority of clinicians surveyed
nationally employ this regimen, although 21.3% wait 6 hours
after amniotomy before starting oxytocin.  
Another interesting fact that came to light in this study was
that most obstetricians in South Africa would not use oxytocin
for either induction or augmentation of labour in a patient with
a previous (lower-segment) caesarean section.  Could this
possibly be explained by Edwin Cragin’s well-known
statement in 1916:  ‘once a caesarean, always a caesarean’?20
One of the biggest fears among obstetricians who allow a trial
of scar is the risk of uterine rupture.  Arulkumaran et al.21
reported the risk of scar rupture to be small if progress of
labour in response to oxytocin is satisfactory.  They suggested
that a satisfactory rate of cervical dilatation in the presence of
optimal uterine activity is predictive of a favourable outcome
when oxytocin is used for dysfunctional labour after a previous
caesarean section.21
Several studies22-27 consider the risk of scar rupture in patients
with a previous caesarean section who received oxytocin for
either induction or augmentation of labour (Table II). Flamm et
al.23 had no uterine rupture in their study and no maternal or
perinatal mortality. Paul et al.25 investigated low-dose oxytocin
use in patients with a scarred uterus and found a dehiscence
rate of 3%. There was no ‘true’ rupture secondary to oxytocin
use. In 1991 Rosen et al.28 published a meta-analysis describing
the morbidity of vaginal birth after caesarean section.  It
included 31 studies with more than 11 000 patients, and the
(intended) route of delivery was observed to have made no
difference to the rate of uterine dehiscence or rupture.  The use
of oxytocin, a recurrent indication for the previous caesarean
section and the presence of an unknown type of uterine scar
were also not associated with dehiscence or rupture.28
This study showed that obstetricians are reluctant to use
oxytocin for either induction or augmentation of labour in
patients with multifetal pregnancies.  The literature on the use
of oxytocin in twin pregnancies is very limited.  In 1967
Niemand et al.29 looked at the use of oxytocin augmentation in
127 women with twin pregnancies, of whom two-thirds were
multigravid.  Oxytocin was commenced during the first stage
of labour and continued through to the third stage.  They
suggested that overdistension of the uterus is apparently not a
contraindication to intravenous oxytocin and that there are no
significant untoward effects from its use.  Eighty-five per cent
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of women who displayed the dysfunctional type of labour
commonly found in twins had vaginal deliveries. Fausett et al.30
published a retrospective study in 1997 comparing twin with
singleton pregnancies in terms of maximum dose of oxytocin
used and successful vaginal deliveries.  Oxytocin stimulation in
twins resulted in fewer interruptions of the infusion for fetal
heart rate abnormalities (5% for twins versus 26% for singleton
pregnancies) and less hyperstimulation (6% v. 18%). 
Recently Harle et al.31 conducted a case-controlled study
comparing oxytocin induction with expectant management in
uncomplicated twin pregnancies. They concluded that
induction of labour may be proposed to patients with
uncomplicated twin pregnancies after 36 weeks’ gestation
without increasing maternal or fetal morbidity. 
Despite the literature, doctors are still hesitant to use
oxytocin for either induction or augmentation of labour in
patients with multifetal pregnancies, as is evident in this study.
According to the Royal College of Obstetricians and Gynae-
cologists (RCOG)32 no conclusion can be drawn from the
available evidence regarding the merits of an active policy for
induction of labour in twin pregnancies.  If there is careful
monitoring of both the fetus and the mother and if the
presenting twin is cephalic, oxytocin may be used with caution
in twin pregnancies.  
Almost 70% of South African obstetricians were reluctant to
use oxytocin in a grand-multiparous patient, whether for
induction or augmentation of labour.  The data on oxytocin use
in grand-multiparous patients are very limited.  Ben-Aroya et
al.33 published a retrospective study in 2001. Their objective was
to determine whether the use of oxytocin for the augmentation
of labour in grand-multiparous women would increase the risk
of peripartum complications.  During the period from 1989 to
1997, 424 grand-multiparous women received intravenous
oxytocin for augmentation of labour.  All the women had fetal
heart rate and uterine contraction monitoring.  There was no
significant difference between the oxytocin group and the
control group regarding the rates of placental abruption, fetal
distress, caesarean section, retained placenta and Apgar scores
of less than seven at 5 minutes.  They did, however, find a
significantly higher vacuum delivery rate in the oxytocin group
compared with the controls (3.5% v. 1.4% respectively, p = 0.001). 
One should exercise caution in augmenting multiparous
patients, especially grand multiparas, where the cause of poor
progress may be unrecognised disproportion.  Augmentation
with oxytocin might lead to uterine rupture and fetal death.
Any excessive stimulation of the uterus should therefore be
very carefully avoided, or diagnosed early when oxytocin is
used in the multiparous or grand-multiparous patient.  
Regarding the administration of oxytocin, 74.7% of South
African obstetricians are satisfied with 3 strong contractions in
10 minutes, whereas 21.1% said they would increase oxytocin
infusion until there are 4 strong contractions per 10 minutes.
Some institutions use the cut-off of 5 contractions per 10
minutes with at least 1 minute of uterine diastole,34 but the
RCOG recommends a maximum of 3 strong contractions every
10 minutes,32 and this study confirmed this policy.  
Several articles have been published regarding the
incremental interval (ranging from 15 minutes to 60 minutes)
of oxytocin increase.  If one bears in mind that a stable uterine
response is only obtained 40 - 60 minutes after initiating a
constant oxytocin dose infusion, then in order to prevent
uterine hyperstimulation, oxytocin should only be increased
every 30 minutes.  Most reports32 indicate that the use of longer
intervals between increases reduces uterine hyperstimulation,
decreases the maximum used and total dose of oxytocin and
decreases the rate of caesarean section. The American College
of Obstetricians and Gynecologists35 also recommends 30-
minute incremental intervals. Orhue36 et al. stated that 
30-minute incremental increases in the infusion rate of oxytocin
were superior to a 15-minute protocol in reducing the
incidence of hyperstimulation and precipitous labour in
nulliparous women.
The use of oxytocin has been associated with possible side-
effects for both the mother and fetus.  An important adverse
effect of administering oxytocin is its antidiuretic action.37 This
effect decreases urine flow and places women receiving
oxytocin at increased risk of dilutional hyponatraemia (water
intoxication).  Therefore the total fluid intake during oxytocin
administration should be monitored carefully.38  The develop-
ment of dilutional hyponatraemia is enhanced when oxytocin
is administered in an electrolyte-free dextrose solution or at a
rate exceeding 20 mU/min.39 The preferred solutions are
Table II. Successful oxytocin administration during trials of labour after previous caesarean sections 
Oxytocin No oxytocin 
Vaginal 
Series Year Trials of labour Vaginal delivery (%) Trials of labour delivery (%) 
Meehan22 1988 261 235  (90) 298 240 (81)
Flamm et al.23 1987 282 194 (69) 1 291 1 005 (78)
Silver and Gibbs24 1987 64 40 (63) N/A N/A
Paul et al.25 1985 257 177 (69) 594 537 (90)
Chelmow and Laros26 1992 62 46 (74) 442 245 (55)
Phelan et al.27 1987 793 557 (70) N/A N/A
therefore either 0.9% sodium chloride or lactated Ringer’s
solution.  
Oxytocin appears to have a high therapeutic index because
broad ranges of infusion rates and concentrations seem to be
both safe and effective.34 O’Driscoll et al.40 introduced active
management of labour in nulliparous women to shorten labour
at a time when the caesarean section rate was stable at 6%.
Their regimen included early amniotomy and prompt inter-
vention with high-dose oxytocin in the event of inefficient
uterine contractions. However the efficacy and safety of this
protocol was not universally accepted.  Locally, Pattinson et al.41
compared labour outcomes in nulliparous women using either
aggressive or expectant management protocols, and concluded
that aggressive labour management reduces the caesarean
section rate in nulliparous women, but it requires more
intensive nursing. Satin et al.42 studied a high-dose oxytocin
regimen (6 mU/minute dosage increments) versus a low-dose
regimen (1 mU/minute dosage increment) for labour
Table III. Oxytocin — international recommendation v. South African obstetrician use
International recommendation South African use
Induction of labour
1.  Primigravida : time after ROM 1 hour* Immediately: 18.9%
After 1 hour:  36.7%
After 6 hours: 21.3%
After 12 hours: 6.5%
2.   Multigravida: time after ROM 1 hour* Immediately: 11.8%
After 1 hour: 30.8%
After 6 hours: 33.1%
After 12 hours: 5.9%
3.   Use with 1 previous c/s Not contraindicated20,27 29.7% use oxytocin
4.   Use with viable twins Few data 36.3% use oxytocin
Probably safe30
Augmentation of labour
1.   Use with 1 previous CS Not contraindicated20,27 34.6% use oxytocin
2.   Use with viable twins Few data 39.3% use oxytocin
Probably safe30
3.   Use with multipara No data 91.9% use oxytocin
4.   Use with grand multipara No data 27.7% use oxytocin
Probably dangerous
5.   Desired number of contractions 3 in 10 minutes33 2: 1.2%
3: 74.7%
4: 21.2%
5: 3%
6.   Fetal heart rate monitoring Continuous CTG 68.3%
7.   Time after prostaglandin use 6 hours16 1 hour: 2.6%
2 hours: 5.8%
4 hours: 25.6%
6 hours: 50%
8.   Increment intervals 30 min34 15 min: 14.6%
30 min: 71.9%
45 min: 7.9%
60 min: 4.9%
*Acceptable practice.
CS = caesarean section; CTG = cardiotocogram.
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stimulation.  They found that the high-dose regimen was
associated with a significantly increased caesarean section rate
for fetal distress (6% v. 3%, p = 0.05), but a lower incidence of
instrumental deliveries, fewer caesarean sections for dystocia
and fewer failed inductions. 
The present study required obstetricians to state the
regimens used in their units, but unfortunately this specific
question was answered poorly and no conclusion could be
drawn.  It is clear that many different regimens are used by
clinicians.  The RCOG guidelines33 recommend that oxytocin
infusions should be given in the smallest possible volume,
using an accurate infusion pump and should be commenced at
a rate of  1 mU/min, increased at intervals of not less than 30
minutes (until 3 strong contractions every 10 minutes) up to a
maximum rate of 12 mU/min. According to the guidelines the
total dose of oxytocin used should not exceed 5 units. 
To the best of our knowledge this study is the first of its kind
to be conducted in South Africa. It is reassuring to note that
most of the obstetricians in South Africa follow accepted
practice (Table III). However, as demonstrated by their limited
use of oxytocin in women who had previous caesarean sections
or with twin pregnancies, their approach is too cautious. It is
very reassuring that most obstetricians use continuous fetal
heart rate monitoring, and that the others use intermittent
monitoring in some way or another. No one used auscultation
exclusively in these cases. On the other hand, it is also
alarming that some obstetricians use unsafe practices such as
the use of oxytocin immediately after the membranes have
been ruptured or within 6 hours of prostaglandins having been
used, and that they increase the dose rate every 15 minutes or
try to achieve a contraction frequency of 5 in 10 minutes. It is
essential that these potentially dangerous practices are
addressed in continuing professional development
programmes.
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